- Home
- RJET vs VALN Comparison
RJET vs VALN Comparison
Compare RJET & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RJET | VALN |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 855.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RJET | VALN |
|---|---|---|
| Price | $17.41 | $9.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 78.4K | 23.8K |
| Earning Date | 02-08-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 93.20 | N/A |
| Revenue | ★ $1,597,200,000.00 | $211,089,992.00 |
| Revenue This Year | N/A | $3.64 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | 11.76 | ★ 13.48 |
| 52 Week Low | $17.35 | $4.22 |
| 52 Week High | $22.03 | $12.25 |
Technical Indicators
Market Signals| Indicator | RJET | VALN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.79 |
| Support Level | N/A | $9.85 |
| Resistance Level | N/A | $10.37 |
| Average True Range (ATR) | 0.00 | 0.36 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 78.70 |
Price Performance
Historical ComparisonAbout RJET Republic Airways Holdings Inc.
Republic Airways Holdings Inc operates a fleet of 240+ Embraer 170/175 aircraft and offers scheduled passenger service with daily flights to cities across the U.S., Canada, the Caribbean and Central America.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.